Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGENT 797

Next Previous
X
Search
Drug Profile

AGENT 797

Alternative Names: AGENT-797; Allogeneic iNKT cell therapies - Agenus; Unmodified iNKT cell therapies - Agenus

Latest Information Update: 23 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus
  • Developer Agenus; MiNK Therapeutics
  • Class Antineoplastics; Antivirals; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Solid tumours
  • Phase I/II SARS-CoV-2 acute respiratory disease
  • Preclinical Graft-versus-host disease
  • No development reported Multiple myeloma

Most Recent Events

  • 23 Dec 2024 9432622: No update, company to present data
  • 14 Nov 2024 MiNK Therapeutics plans a phase I trial for Graft-versus-host-disease in USA and European Union in 2025
  • 15 Oct 2024 MiNK Therapeutics in collaboration with Autonomous Therapeutics plans a phase I trial for Solid tumours (Second-line therapy or greater, Combination therapy, Metastatic disease) (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top